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Reinstalling the neurobiological circuits to effectively change the debilitating course
of neurodegenerative diseases is of utmost importance. This reinstallation requires
generation of new cells which are able to differentiate into specific types of neurons and
modification of the local environment suitable for integration of these new neurons into the
neuronal circuits. Allopregnanolone (APα) seems to be involved in both of these processes,
and therefore, is a potential neurotrophic agent. Loss of dopamine neurons in the
substantia nigra (SN) is one of the main pathological features of Parkinson’s and also in, at
least, a subset of Alzheimer’s patients. Therefore, reinstallation of the dopamine neurons in
nigrostriatal tract is of unique importance for these neurodegenerative diseases. However,
for the neurogenic status and the roles of allopregnanolone in the nigrostriatal tract, the
evidence is accumulating and debating. This review summarizes recent studies regarding
the neurogenic status in the nigrostriatal tract. Furthermore, special attention is placed
on evidence suggesting that reductions in allopregnenalone levels are one of the major
pathological features in PD and AD. This evidence has also been confirmed in brains
of mice that were lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or
those bearing neurodegenerative mutations. Lastly, we highlight studies showing that
allopregnanalone can augment the number of total cells and dopaminergic neurons via
peripheral exogenous administration.
Keywords: allopregnanolone, neurogenesis, substantia nigra, nigrostriatal, tyrosine hydoxylase, neural circuits,
motor performance
INTRODUCTION
Research data consistently suggests that a small molecule, the
neurosteroid allopregnanolone (APα) capable of permeating the
brain-blood-barrier, is a latent restorative therapeutic agent for
reestablishing neuronal circuits in hippocampus and also the
nigrostrital tract. Supportive data demonstrated that APα func-
tioned as a neurotrophic factor for human, rat, and mouse neural
progenitor cells (Keller et al., 2004; Wang et al., 2005, 2010;
Charalampopoulos et al., 2008) and augmented the number of
cells in the hippocampus and reversed deficits in learning and
memory in a mouse model for Alzheimer’s disease (3xTgAD,
a triple transgenic with APPSwe, PS1M146V, tauP301L) (Wang
et al., 2010; Chen et al., 2011; Singh et al., 2012), for review
see Brinton (2013) and Irwin and Brinton (2014). In con-
trast, APα has been reported to inhibit the learning and mem-
ory when chronically treated for 3 months (Bengtsson et al.,
2012, 2013) and the potential mechanisms for this discrep-
ancy have been discussed elsewhere (Brinton, 2013; Wang, 2013;
Irwin and Brinton, 2014). In addition, APα also plays a role
in regulating depressive episodes (Schüle et al., 2011, 2014;
Evans et al., 2012; Hellgren et al., 2014) and the antidepres-
sant effects of APα is probably mediated via neurogenesis in
dentate gyrus in hippocampus (Evans et al., 2012). Recently,
accumulated data indicated that APα increased the number of
total cells, tyrosine hydroxylase (TH) positive cells, and newly
formed (BrdU positive) TH expressing cells in the substantia nigra
(SN), and improved the balance and coordination of 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice, an
animal model for Parkinson’s disease (PD; Adeosun et al., 2012).
The augmentation of TH positive neurons by APα in the SN of
3xTgAD mice (Sun et al., 2012a) clarified that APα accomplished
its role through the reestablishment of DA neuronal architec-
ture, rather than blockading the neurotoxic effects of MPTP.
This review summarizes and highlights the current discoveries
involving the generation of new neurons in the nigrostriatal tract
and the therapeutic potential for the related neuronal disorders of
APα.
THE SIGNIFICANCE FOR A THERAPEUTIC STRATEGY TO
REINSTALL THE FUNCTIONAL DA NEURONS IN
NIGROSTRIATAL TRACT
AD and PD are devastating, degenerating neural disorders which
currently cannot be cured. More than 5 million and nearly
1 million Americans have AD or PD, respectively, and every
minute a new case is added in this cohort. These diseases not
only bring about suffering for the patients themselves, it is
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also a heavy financial burden and high labor cost for both the
families and society. The severity of these diseases is closely
related to the number of neurons that are lost in specific brain
regions.
For example, the symptoms of PD are closely associated with
the depletion of striatal dopamine (DA), brought on by the
impairment of normal neurobiological architecture of neural cells
in the nigrostriatal tract, resulting in the degeneration and death
of DA neurons. The role of nigrastriatal tract in AD has been
reported in studies using post-mortem brains from patient with
AD, transgenic mice with human AD mutations, and also from
those studying the dopamine effects in AD (Uchihara et al.,
1992; Love et al., 1996; Perez et al., 2005; Nardone et al., 2014).
Diffuse plaques in the striatum and neurofibrillary tangles in
the SN were consistent findings in all of the Alzheimer brains
tested (Uchihara et al., 1992; Love et al., 1996). Furfuremore, a
41% significant neuronal loss was observed in SN of AD subjects
compared to that in the age matched controls (Uchihara et al.,
1992). Although in the study by Love et al. (1996), quantitation
did not reveal a statistically significant correlation between the
density of striatal plaques and the numbers of either neurofib-
rillary tangles or neurons in the SN in “pure” AD (i.e., without
clinical or neuropathological evidence of Parkinson’s or corti-
cal Lewy body disease), the mean number of neurons in the
SN of Alzheimer brains was lower than that in controls (Love
et al., 1996). Pharmacologically, L-Dopa significantly increased
Short-latency afferent inhibition (SAI) in the AD patients, while
it failed to restore SAI abnormality in patients with Cerebral
Autosomal Dominant Arteriopathy with Sub-cortical Infarcts
(Nardone et al., 2014). Therefore, L-Dopa-mediated changes on
SAI in AD patients seem to be a specific effect. The striatum
and the SN of transgenic mice harboring familial AD (FAD)-
linked APPswe/PS1DeltaE9 mutants exhibit morphological alter-
ations accompanied by amyloid-beta (Aβ) deposition 6 months
of age, and the extent of deposition increases in an age-dependent
manner (Perez et al., 2005). In addition, a reduction in the
dopamine metabolite DOPAC was also observed in the striatum
of these mice (Perez et al., 2005). These findings suggested a
close association between amyloid deposition and nigrostriatal
pathology and suggest that altered familial AD-linked amyloid
metabolism impairs, at least in part, the function of dopaminergic
neurons.
L-DOPA treatment and deep brain stimulation only provide
symptomatic relief by increasing brain DA levels without alter-
ing the course of the disease. Scientists have been attempting
to adjust the developmental course of the disease by restor-
ing region-specific DA neuron architecture (Soderstrom et al.,
2006). Initial trials to replenish DA neurons used grafts of DA-
producing adult adrenomedullary tissue and then fetal mesen-
cephalic tissue (Collier et al., 2002; Williams and Lavik, 2009;
Lindvall and Kokaia, 2010), but encountered many obstacles
(Björklund, 1993). Recent discoveries overcame these hurdles
by generating patient-derived pluripotent and growth factor-
enhanced fibroblasts to increase the supply of tissue for grafting
and to prevent transplant rejection. However, new problems have
materialized. It is still not clear whether grafted cells will survive
in a pathological environment with a deteriorated milieu and
be appropriately integrated into a >50-year-old local neuronal
network. In fact, patients in clinical trials with grafted cells
emerged with dyskinesia (Freed, 2002; Maries et al., 2006). This
data implicates that the grafted new cells were not integrated into
the existing neuronal network and were not capable of performing
the expected functions. Interestingly, PD pathological markers,
Lewy bodies and α-synuclein aggregates, had been observed in
the grafted cells (Li et al., 2008; Hansen et al., 2011). Thus, there
is an urgent need for a therapeutic strategy to restore functional
DA neurons, which could effectively integrate into the existing
neuronal network.
APα IMPROVES BALANCE AND COORDINATION AND
INCREASES THE NUMBER OF NEW TYROSINE
HYDROXYLASE CELLS IN SNpc OF MPTP-LESIONED MICE
MPTP-lesion impairs the motor performance, particularly in
the modalities of balance and coordination, in C57BL/6J mice
(Antzoulatos et al., 2010). The balance and coordination of
MPTP-lesioned mice were improved in a rotarod performance
task in which mice were forced to move correctly to prevent
them from falling. Mice that received peripheral administration
of APα almost completely regained their ability to walk on the rod
(Adeosun et al., 2012). Correlated to the improvement of motor
performance, the number of tyrosine hydroxylase immunoreac-
tive (TH-IR) cells in the SN in APα-treated, MPTP-lesioned mice
was increased. This data suggests that APα promotes the reinstal-
lation of functional neural circuits in the nigrostriatal pathway
either by reversal (recovery) of the MPTP-induced degeneration
of TH neurons, and/or the generation of new (or differentiated)
TH-expressing neurons in this brain region. In addition to the
increase of TH-IR neurons, APα also increased the number
of Nissl stained cells, which were both reduced in mice only
received the MPTP neurotoxin. These results, in addition to the
increase of BrdU/TH double positive cells in APα-treated mice,
suggest that new cells, not only TH-IR neurons but also the non-
neuronal cells, were added into the SN of the MPTP-lesioned mice
(Adeosun et al., 2012; Figure 1).
It is still in debate whether neurogenesis also occurs in the
SN. Studies from different groups demonstrated that new cells
were born in the healthy SN (Lie et al., 2002; Zhao et al.,
2003). The precursor cells isolated from the SN had the ability
to differentiate into neurons in vitro (Lie et al., 2002) or the
generation of new mature nigral DA neurons under physiological
conditions by colocalization of BrdU and TH (Zhao et al., 2003).
In contrast, opposite report indicated that there is no evidence
for neurogenesis in SN (Frielingsdorf et al., 2004) and argued
that the BrdU and TH co-localization was an overlay of a BrdU
positive glia on an adjacent neuron (Borta and Hoglinger, 2007).
However, a number of works have also described the expression
of polysialylated-neural cell adhesion molecule (PSA-NCAM), a
molecular expressed in multipotent progenitor cells, in the cells of
SN (Nomura et al., 2000; Yoshimi et al., 2005) and a small number
of cells are PSA-NCAM double positive (Yoshimi et al., 2005).
Borta and Hoglinger (2007) discussed that PSA-NCAM is also
expressed in other cells undergoing plastic changes, and therefore,
these results do not support the hypothesis of dopaminergic
neurogenesis in the SN. Peng et al. reported that fibroblast growth
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FIGURE 1 | New TH expressing neurons in SNpc of allopreganolone
treated mice lesioned by MPTP. A 3-dimensionally rotated
double-immunolabeling image shows a new neuron (red, BrdU positive in
nuclear) expressing TH (green in cytoplasm and neurites), and a few TH
positive only neurons marked with *. Similar image can be found in
Adeosun et al. (2012).
factor 2 increased the number of BrdU and doublecortin double
positive cells in SN of MPTP-lesioned mice (Peng et al., 2008).
Others reported that either physical activity or Unilateral lesion
of the subthalamic nucleus increased the oligodendrogenesis and
astrogliogenesis in the SN after 6-OHDA lesion (Steiner et al.,
2008; Klaissle et al., 2012). Recently, it was also reported that the
majority of newly generated cells in the adult mouse SN express
low levels of doublecortin (Worlitzer et al., 2013). Taken together,
these data support the generation of new cells in SN, but whether
these new cells will differentiate into functional DA neurons is
not clear. Perhaps by reestablishing the extracellular milieu and
local environment in SN to a level suitable for new neuron
differentiation, maturation and integration into the existing neu-
ronal circuits will be a hopeful solution. In addition, appropriate
labeling protocols may be needed to identify the newly generated
neurons by optimized amount of BrdU (Zhao and Janson Lang,
2009), or by tracing the ratio of C14 in DNA of cells in striatum of
human brains (Ernst et al., 2014).
Accumulated evidence suggests that there are multiple neu-
rogenic niches in the brain apart from the hippocampal dentate
gyrus sub granular zone (SGZ) and the cerebral sub ventricular
zone (SVZ). These include the hypothalamus (Lee et al., 2012),
cerebellum (Keller et al., 2004; Ponti et al., 2005, 2006, 2008, 2010;
Bonfanti and Ponti, 2008; Hajihosseini et al., 2008), striatum
(Tattersfield et al., 2004; Ninomiya et al., 2006; Luzzati et al.,
2007; Snyder et al., 2010; Danilov et al., 2012; Delavaran et al.,
2013; Ernst et al., 2014; Kempermann, 2014), and SN (Bayer
et al., 1995; Zhao et al., 2003; Chen et al., 2005; Van Kampen
and Robertson, 2005; Yoshimi et al., 2005; Arias-Carrión et al.,
2006, 2009; Freundlieb et al., 2006; Shan et al., 2006; Steiner
et al., 2006; Esposito et al., 2007; Mandel et al., 2007; Di Giovanni
et al., 2009; Ries et al., 2009; Park et al., 2012; Sun et al.,
2012a,b; Worlitzer et al., 2013). Therefore, APα may promote
the generation of new cells locally in SN. One such possibility is
that APα increases proliferation of glial fibrillary acidic protein
(GFAP), or Ng2 expressing glia cells, which maintain their mitotic
status, and drives the differentiation of these new cells into DA
neurons in the SN. This hypothesis is supported by the recent
studies demonstrating that the primary progenitors in adult
neurogenesis are astrocyte-like cells that express GFAP and that
surviving cells exhibit neurites 7 days after proliferation (Cabras
et al., 2010; Ming and Song, 2011). Furthermore, it has also
been reported that, in the presence of sonic hedgehog, GFAP-
expressing mesencephalic progenitor cells can be differentiated
into TH-IR neurons within 4 days (Matsuura et al., 2001).
Parallelly, the new adult subependyma cells (BrdU positive) of
the lateral ventricle can differentiate into TH-expressing neurons
after 24-h exposure to fibroblast growth factor (bFGF2) and glial
cell conditioned media (Daadi and Weiss, 1999). Therefore, it
is possible that in the SN, the proliferating glial-like cells have
the capacity to differentiate into both neurons and glial cells as
regulated by their microenvironment. This is further supported
by a recent study which demonstrate that glia cells can dif-
ferentiate into neurons in the presence of neuronal differentia-
tion 1, a basic helix-loop-helix transcription factor (Guo et al.,
2014).
APα IS A POTENTIAL NEUROGENIC AGENT IN
NIGROSTRIATAL TRACT
The neurotrophic feature of APα is widely supported by the
literature. APα is produced in pluripotent progenitor cells (Lauber
and Lichtensteiger, 1996; Gago et al., 2004) and neurons (Pinna
et al., 2004; Agís-Balboa et al., 2006) throughout the embryonic
period. In late gestation, a developing period in which large
amount of CNS neurons are generated and functional circuits
are formed, APα concentration is 20–30 times higher than any
other time in life (Pomata et al., 2000). In pathological conditions,
the concentration of APα is significantly reduced in the brains of
humans with AD (Marx et al., 2006; Smith et al., 2006; Naylor
et al., 2010), with PD (di Michele et al., 2003; Luchetti et al., 2010)
as well as from the brains of a transgenic mouse model of AD
(Wang et al., 2007, 2010). More interestingly, the lower the APα
concentration, the more severe these neurodegenerative diseases
are and the pathology appears to be inversely correlated with the
levels of APα (Naylor et al., 2010).
In mice lesioned with MPTP, APα reversed the cell number
decline of TH-expressing and Nissl positive cells in both SN and
Locus coeruleus (LC; Adeosun et al., 2012). This data suggest
that the generation of new cells by APα is not cell type, brain
region, or mouse model specific, as we previously reported the
neurogenic property of APα in the SGZ and SVZ in a mouse
model of AD (Wang et al., 2010; Chen et al., 2011; Singh et al.,
2012). The fact that APα increased the proliferation of cerebellar
neurogenic cells supports the observation that APα is not only
a neurogenic agent in known neurogenic areas such as SGZ and
SVZ, but also in brain regions such as the cerebellum (Keller
et al., 2004) and the SNpc (Adeosun et al., 2012; Sun et al.,
2012a).
Interestingly, it appears that the neurogenic effects of APα need
to be enhanced or maintained with physical activities (Adeosun
et al., 2012). In support, utilizing running wheels or forced
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treadmill for several weeks increased the TH expression (Gerecke
et al., 2010; Tajiri et al., 2010). Moreover, a significant increase
in numbers of newborn NG2-positive and GFAP-positive cells
was observed in the SN of 6-OHDA lesioned animals living in
enriched environment with physical activity for 7 weeks. These
mice showed improved motor behavior compared to controls
under standard conditions (Steiner et al., 2006). Therefore, it is
likely that forced physical activity helps the survival and differen-
tiation of newly formed cells induced by APα. This point of view
is supported by the fact that newly formed neural progenitors
can differentiate into TH-expressing neurons within 24 h when
exposed to glial cell conditioned media or basic bFGF2 (Daadi
and Weiss, 1999), and in line with report that bFGF2 expres-
sion is increased after physical exercise (Gómez-Pinilla et al.,
1997).
APα FUNCTIONS IN THE NIGROSTRIATAL TRACT OF MICE
WITH AD MUTATIONS
Is APα only a blockade for MPTP-lesion, or a neurogenic agent
in the SN? Recent work demonstrating that APα also increases
TH positive neurons and total cell numbers in the SN of a triple
transgenic mouse for AD (3xTgAD) Sun et al. (2012a) clarified
that APα played its role through reestablishment of DA neuronal
architecture, rather than by the blockade of the neurotoxic func-
tion of MPTP. Further support is from reports that genetic risk
factors found in familial AD (i.e., mutations in APP, PS1 and tau
phosphorylation genes) also play a role in SNpc neuropathology
and atrophy.
Besides the occurrence of plaques, tangles and hippocampal
atrophy, atrophy in brain nuclei containing TH expressing neu-
rons is also a neuropathological feature of late-onset AD (Chui
et al., 1986; LaFerla et al., 1997; Zarow et al., 2003). For example,
a meta-analysis concluded a consistently high TH neuron loss
(52–76%) in LC, and a variable neuron loss (4–50%) in the SNpc
in post-mortem brains of late onset AD subjects (Zarow et al.,
2003). These data indicate that reduction of TH expressing and
total neurons in SN of animals bearing AD mutations (Sun et al.,
2012a) occurs, and is in agreement with those early studies from
AD subjects (Zarow et al., 2003).
Supportive evidence was also emerged from the transgenic
APP/PS1 mouse model of AD, in which hyper-accumulated Aβ-42
residues lead to the early appearance of amyloid plaque formation
when compared to mice with only the single transgene APP (Perez
et al., 2005; O’Neil et al., 2007). In the APP/PS1 double mutant
mice there was a significant (24%) reduction in TH-positive
neurons in the LC in comparison to their background controls
(O’Neil et al., 2007). Interestingly, the loss of TH expressing
neurons was not observed in the transgenic mouse model with
APP23 (Szot et al., 2009) nor PADPP (German et al., 2005). These
findings suggest that the loss of TH positive neurons may be a
result of the double APP/PS1 mutations, rather than a single APP
mutation.
It has been proposed that tau protein abnormalities play a
more important role in the loss of neurons in AD, and that
deposition of amyloid plaques does not correlate well with neuron
loss (Mudher and Lovestone, 2002; Mudher et al., 2004; Schmitz
et al., 2004). Neurofibrillary tangle formation is composed of
hyperphosphorylated microtubule-associated protein tau that
appears to accumulate within vulnerable neurons and may even-
tually kill the cell, leaving behind only a ghost tangle and no
neuron (Ramsden et al., 2005; Iqbal and Grundke-Iqbal, 2006;
Gong and Iqbal, 2008). The 3xTg mice carry, in addition to
two mutations in human familial AD genes (APPSwe, PS1M146V),
one frontal temporal dementia-linked tau mutation (tauP301L)
and mimic multiple aspects of AD neuropathology in relevant
brain regions (Oddo et al., 2003a,b). The reduction of TH-
immunoreactive neurons in the SNpc of 3xTgAD male mice
at 3 months old, extend the previous report and supports the
hypothesis that early neurogenic deficits lead to the reduction
of total neuron numbers in multiple brain regions of AD sub-
jects (Wang and Sun, 2010) including SNpc. SN lesions are
frequently present in AD and include pigmented neuronal cell
loss, gliosis, Lewy bodies, α-synuclein-stained structures, and
hyperphosphorylated tau accumulation in neurofibrillary tangles
as well as neuritis (Kazee et al., 1995; Klunk et al., 2004; Burns
et al., 2005), suggesting that AD is a significant risk factor for
SN lesions (Kazee et al., 1995; Kazee and Han, 1995). APα-
induced neurogenesis is dose-dependent and the most effective
dose in vitro also has neurogenic effects in vivo that are accom-
panied with a reversal of the cognitive deficits in 3xTgAD mice
(Wang et al., 2005, 2010). Previous studies indicated biphasic
dose-dependent efficacy of APα on neurogenesis (Wang et al.,
2005, 2010). At 100, 250, and 500 nM concentrations, APα
significantly increased BrdU incorporation (lower concentrations
were not statistically different from the control). At 1000 nM, a
reversal of the dose–response was first apparent, with higher doses
shifting the response to significant repression of proliferation
at 100–1000 nM. A recent study titrated the optimal regimen
for therapeutic efficacy of APα treatment in vivo in 3xTgAd
mice (Chen et al., 2011). In both APα treatment regimens of a
single exposure of 1/month and of repeated expose (1/week/6
months), APα treatment significantly increased the survival of
cells that were generated at the first exposure to APα. The repeated
exposure (1/week/6 months) APα treatment regimen had greater
regenerative efficacy. However, the 3/week/3 months regimen
significantly reduced regenerative efficacy (Chen et al., 2011). This
once per week regimen suggested there might be a 7-day cycle
which could help reach the best effects of APα and this seems
consistent with the role of APα in SN (Adeosun et al., 2012; Sun
et al., 2012a).
In contrast, recent work by Bengtsson and colleagues demon-
strated that constant infusion of APα (via ALZET mini-pumps)
for 3 months increase GABAergic function/inhibition in brain.
These levels of APα showed a negative impact on both learn-
ing and memory and neuropathology of amyloid beta depo-
sition (Bengtsson et al., 2012, 2013; Wang, 2013). Results
of these investigations are in line with learning and mem-
ory deficits experienced by people who are chronically treated
with high levels of anti-seizure medications. Mechanistically,
this may be due to the accumulation of APα in the brain
with a final concentration high enough to enter the second
phase (inhibition) of the dose response of APα on neuroge-
nesis (Wang et al., 2005; Brinton, 2013; Irwin and Brinton,
2014).
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Wang and Brinton reported that APα transiently increases
intracellular calcium concentration in primary cultured hip-
pocampal neurons. This intracellular calcium increase is mediated
by GABAA receptor and L-type Calcium Channel (Wang and
Brinton, 2008) and this calcium increase is related to neural
progenitor cell proliferation in vitro (Wang et al., 2005) and
in vivo (Wang et al., 2010). The APα induced transient increase
of intracellular calcium concentration and the subsequent prolif-
eration of progenitor cells was abolished by inhibitors for GABAA
receptor and voltage gated calcium channel blockers (Wang and
Brinton, 2008). Therefore, it is likely the effects of APα on the
increase of new neurons and cells are also mediated by GABAA
receptor regulated transient increase of calcium concentration,
however, more experimental evidence is needed.
SUMMARY AND POTENTIAL EXPECTATION
In summary, research demonstrates that the levels of APα, are
reduced in the brains of subjects with AD or PD. The promising
role of this APα therapy in AD and PD is supported by the recent
work that peripheral administration of APα, with its ability to
permeate the blood brain barrier, could improve cognitive and
motor performance and increase the number of DA neurons in
the SN of mice lesioned by MPTP and mice with AD mutations.
These results support that APα accomplishes its role through the
reestablishment of dopamine neuronal architecture, rather than
blockading the neurotoxic effects of MPTP.
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